item management s discussion and analysis of financial condition and results of operations statements included herein which are not historical facts are forward looking statements 
such forward looking statements are made pursuant to the safe harbor provisions of the private securities litigation reform act of the forward looking statements involve a number of risks and uncertainties  including but not limited to  changes in economic conditions  demand for the company s products  pricing pressures  intense competition in the industries in which the company operates  the need for the company to keep pace with technological developments and timely respond to changes in customer needs  the company s dependence on third party suppliers  the effect on foreign sales of currency fluctuations  acceptance of new products  consistency in the level of orders for custom bioprocess systems  the ability of dgi to achieve its scientific objectives and enter into corporate partnering and or licensing agreements  the labor relations of the company and its customers and other factors identified in the company s securities and exchange commission filings 
results of operations vs 
for the year ended december   the company had net income of  or 
per diluted share on net sales of  compared with net income of  or 
per diluted share on net sales of  for the year ended december  in  net sales increased due to a increase in us domestic sales and higher sales in the united kingdom which benefited from the delivery of a large custom bioprocess system 
gross margins improved to in from in due to continuing improvements in productivity in the company s manufacturing operations and from the higher component of domestic sales which tends to carry a somewhat higher margin than export sales  a large portion of which go through dealers and distributors 
research  development and engineering expenses increased in primarily to support the operations of dgi biotechnologies  llc dgi  the company s majority owned drug lead discovery operation 
interest income decreased to  in from  in primarily as a result of lower average cash available for investment 
during  the us dollar strengthened against the currencies of the european countries where the company has subsidiary operations 
the effect of these currency movements decreased income from foreign operations by approximately  to  the effects of balance sheet translation resulted in a currency translation adjustment of  which is reflected in the equity section of the consolidated balance sheet 
vs 
for the year ended december   the company had net income of  or 
per diluted share on net sales of  compared with net income of  or 
per diluted share on net sales of  for the year ended december  in sales increased due equally to higher sales in the us domestic market and in western europe 
the increase of in cost of sales is directly attributable to the increase in net sales 
research  development and engineering expenses increased in due primarily to the full year effect of the start up in october of dgi biotechnologies  llc dgi  the company s drug discovery operation 
interest expense increased to  in from  in due primarily to the accrual of interest on deferred compensation 
other income expense  net in of  consisted primarily of bank charges and credit facility renewal fees 
provision for income taxes as a percentage of income before taxes decreased to from in since all of the company s income emanated from its foreign subsidiaries  a significant portion of which is not subject to income taxes due to carryforward tax losses on which income tax benefits were not previously recognized 
us operations were in a net taxable loss situation due to the significant increase in research and development costs in to support the operations of dgi 
during  the us dollar strengthened against two and weakened against one of the currencies of the european countries where the company has subsidiary operations 
the effect of these currency movements decreased income from foreign operations by approximately  to  the effects of balance sheet translation resulted in a currency translation adjustment of  which is reflected in the equity section of the consolidated balance sheet 
financial condition liquidity and capital resources during the year ended december   cash and cash equivalents decreased to  from  at december  the decrease in cash resulted primarily from an increase in inventories to  at december  from  at december   partially offset by an increase in accounts payable and accrued expenses to  at december  from  at december  finished goods inventory increased to  at the end of from  at december   raw materials and sub assemblies increased to  at december  from  at december  and work in process increased to  at december  from  at december  these increases are primarily attributable to an overlap of shaker lines due to the addition of the company s classic line of shakers which is intended to eventually supercede its gyrotory r line of shakers and to orders for custom bioprocess systems which were in process at december  and which are expected to be delivered in accounts payable and accrued expenses increased as a result of higher advance payments from customers which amounted to  at december  vs 
 at december  other liabilities of  at december   consisted of a pension liability which was a non cash item which was offset by a direct reduction in shareholders equity of a like amount 
this pension liability was reduced to zero at december  due to the positive investment performance of the company s defined benefit pension plan 
drug lead discovery business in october  the company entered the drug lead discovery business by forming a new company to develop a novel  small molecule drug discovery platform 
the company  dgi biotechnologies  llc dgi  is majority owned and fully funded by the company and occupies specially designed laboratory space at the company s headquarters facility in edison  new jersey 
dgi s operations have had a significant negative impact on the company s and earnings and will continue to do so during the balance of its development phase  which is expected to last through during and   and  respectively  was charged to operations 
it is currently anticipated that expenditures for will exceed  this amount could be affected by revenues from licensing agreements and other corporate collaborations which are currently being pursued 
recently issued accounting standards in  the financial accounting standards board issued sfas no 
 earnings per share sfas no 

sfas no 
requires the presentation of earnings per share eps information in the form of basic earnings per share and as diluted earnings per share on the face of the income statements 
basic eps excludes dilution and diluted eps reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the company 
as required  the company has reflected sfas no 
in its financial statements and all prior periods have been restated accordingly 
year issues based upon a review of its computer operations  the company has determined that its costs related to the year problem will be insignificant 
the company has no internally developed software that it utilizes for its operations  but uses computer associates manman classic software  version of which  is compatible with the year the company expects to upgrade its system to version in late or early and will receive that upgrade in the normal course of business as a consequence of its maintenance contract with computer associates 
cash flows from operating activities during the year ended december   net cash used by operating activities amounted to  vs 
net cash provided by operating activities of  for the year ended december  the primary reasons for the  net decrease from to were an increase in inventories of  in vs 
an increase of  in  offset by an increase in accounts payable and accrued expenses of  in vs 
an increase of  in  and a decrease in prepaid expenses and other current assets of  in vs 
a decrease of  in cash flows from investing activities net cash used by investing activities which amounted to  in resulted primarily from  of additions to property plant and equipment and  from an investment made in another entity 
in  net cash used was primarily from additions to property  plant and equipment of  and from an investment made in another entity of  cash flows from financing activities during  repayments of  of long term debt were partially offset with the proceeds of  from stock purchase and option plans and in  repayments of long term debt of  were partially offset with proceeds from stock purchase and option plans of  management believes that the resources available to the company  including its line of credit which has been extended to may   are sufficient to meet its near and intermediate term needs  including present funding commitments for dgi  and its strong unleveraged balance sheet provides the basis for any long term financing if the need should arise 

